Key facts for NCD 220.6.20
- Benefit category
- Diagnostic Tests (other)
- Effective date
- 10/13/2023
- Implemented 12/19/2023
- Transmittal
- Transmittal 12364
- Versions published
- 2
TL;DR
NCD 220.6.20 sets Medicare's national policy for beta amyloid positron tomography in dementia and neurodegenerative disease (retired) under the benefit category "Diagnostic Tests (other)", effective 10/13/2023 and implemented 12/19/2023. (Rev. 12364; Issued:11-16-23; Effective:10-13-23; Implementation:12-19-23) It has been revised 1 time since publication and binds every Medicare Administrative Contractor nationally.
Indications and limitations of coverage
(Rev. 12364; Issued:11-16-23; Effective:10-13-23; Implementation:12-19-23)
Effective October 13, 2023, CMS removed NCD 220.6.20, ending CED for PET beta amyloid imaging and permitting Medicare coverage determinations for PET beta amyloid imaging to be made by the Medicare Administrative Contractors under section 1862(a)(1)(A) of the Social Security Act.
Text reproduced from the CMS Medicare Coverage Database record for NCD 220.6.20 version 2. View the original on cms.gov.
Local policies that build on this NCD
1 active Local Coverage Determination cites NCD 220.6.20 among its related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.
- Positron Emission Tomography (PET) Scan for Inflammation and Infection (L39521) · CGS Administrators, LLC
Coverage analysis history
CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links 2 analyses to NCD 220.6.20, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.
- CAG-00431N Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (New, Closed)
- CAG-00431R Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (1st Recon, Closed)
Revision history
11/2023 - The purpose of this Change Request (CR) is to announce that effective October 13, 2023, CMS removed NCD 220.6.20 from Publication 100-03, the NCD Manual, ending coverage with evidence development (CED) for positron emission tomography (PET) beta amyloid imaging and permitting Medicare coverage determinations for PET beta amyloid imaging to be made by the Medicare Administrative Contractors under section 1862(a)(1)(A) of the Social Security Act.
10/2022 - Transmittal 11546, dated August 4, 2022, is being rescinded and replaced by Transmittal 11636,
dated, October 5, 2022, to remove ICD-10 dx codes added in error to NCD 150.3, business requirement 12842.4, and restore ICD-10 dx C91.92 removed in error to NCD 110.23, business requirement 12842.3. All other information remains the same. ( TN 11636 ) (CR12842)
08/2022 - The purpose of this Change Request (CR) is to provide a maintenance update of ICD-10 conversions and other coding updates specific to NCDs. ( TN 11546 ) (CR12842)
07/2017 - This Change Request (CR) constitutes a maintenance update of International Code of Diseases, Tenth Revision (ICD-10) conversions and other coding updates specific to National Coverage Determinations (NCDs). These NCD coding changes are the result of newly available codes, coding revisions to NCDs released separately, or coding feedback received.
Previous NCD coding changes appear in ICD-10 quarterly updates that can be found at: https://www.cms.gov/Medicare/Coverage/CoverageGenInfo/ICD10.html , along with other CRs implementing new policy NCDs. Edits to ICD-10 and other coding updates specific to NCDs will be included in subsequent quarterly releases and individual CRs as appropriate. No policy-related changes are included with the ICD-10 quarterly updates. Any policy-related changes to NCDs continue to be implemented via the current, long-standing NCD process. ( TN 1875 ) (CR10184)
11/2016 - This change request (CR) is the 9th maintenance update of ICD-10 conversions and other coding updates specific to national coverage determinations (NCDs). The majority of the NCDs included are a result of feedback received from previous ICD-10 NCD CR7818, CR8109, CR8197, CR8691, CR9087, CR9252, CR9540, and CR9631. Some are the result of revisions required to other NCD-related CRs released separately.
Edits to ICD-10 and other coding updates specific to NCDs will be included in subsequent, quarterly releases as needed. No policy-related changes are included with these updates. Any policy-related changes to NCDs continue to be implemented via the current, long-standing NCD process. ( TN 1753 ) (CR9751)
08/2016 - This change request (CR) is the 9th maintenance update of ICD-10 conversions and other coding updates specific to national coverage determinations (NCDs). The majority of the NCDs included are a result of feedback received from previous ICD-10 NCD CR7818, CR8109, CR8197, CR8691, CR9087, CR9252, CR9540, and CR9631. Some are the result of revisions required to other NCD-related CRs released separately.
Edits to ICD-10 and other coding updates specific to NCDs will be included in subsequent, quarterly releases as needed. No policy-related changes are included with these updates. Any policy-related changes to NCDs continue to be implemented via the current, long-standing NCD process. ( TN 1708 ) (CR9751)
03/2014 - Transmittal 160, dated February 6, 2014 is being rescinded and replaced by Transmittal 164, dated March 27, 2014 to update the reference to the correct CPM chapter 13 in the first business requirement. All other information remains the same. Effective date: 09/27/2013. Implementation date: 07/07/2014. ( TN 164 ) (CR8526)
02/2014 - The purpose of this Change Request (CR) is that effective for claims with dates of service on or after, September 27, 2013, Medicare will only allow coverage for PET Aß imaging (one PET Aß scan per patient) through coverage with evidence development (CED) to: (1) develop better treatments or prevention strategies for AD, or, as a strategy to identify subpopulations at risk for developing AD, or (2) resolve clinically difficult differential diagnoses (e.g., frontotemporal dementia (FTD) versus AD) where the use of PET Aß imaging appears to improve health outcomes, when the patient is enrolled in an approved clinical study under CED. Effective date: 09/27/2013. Implementation date: 07/07/2014. ( TN 160 ) (CR8526)
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
For teams evaluating QuickIntell software
Evaluate a coverage-review workflow around NCD 220.6.20
Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — NCD 220.6.20
What does NCD 220.6.20 cover?
(Rev. 12364; Issued:11-16-23; Effective:10-13-23; Implementation:12-19-23) The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 220.6.20 take effect?
The current version (2) is effective 10/13/2023, implemented 12/19/2023, published in transmittal 12364. CMS lists 2 versions of this NCD.
Does a Local Coverage Determination override NCD 220.6.20?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
- Medicare Coverage Database national coverage analyses (NCA/CAL report) via the CMS Coverage APIVersion API snapshot 2026-11-16 · effective 2026-11-16 · file national-coverage-ncacal.jsonSHA-256 563369a07b95140a…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.